Skip to main content

Table 3 Therapeutic regimen of 150 patients with cryptococcal meningitis

From: The utility of cerebrospinal fluid white cell count during the prognostic assessment for cryptococcal meningitis patients: a retrospective study

Treatment

All (N = 150)

(n,%)

Good outcome (N = 94)

(n,%)

Bad outcome (N = 56)

(n,%)

P-value

No treatment

16 (10.67)

0 (0.00)

16 (28.57)

0.000

Monotherapy

11 (7.33)

3 (3.19)

8 (14.29)

Two-drug combination

81 (54.00)

54 (57.45)

27 (48.21)

Triple therapy

42 (28.00)

37 (39.36)

5 (8.93)

Antifungal treatment

 AmB

9 (6.00)

3 (3.19)

6 (10.71)

0.079

 FCZ

2 (1.33)

0 (0.00)

2 (3.57)

0.138

 AmB +  5FC

59 (39.33)

40 (42.55)

19 (33.93)

0.296

 AmB + FCZ

9 (6.00)

4 (4.26)

5 (8.93)

0.295

 AmB + VCZ

3 (2.00)

1 (1.06)

2 (3.57)

0.556

 FCZ +  5-FC

4 (2.67)

3 (3.19)

1 (1.79)

1.000

 VCZ +  5-FC

6 (4.00)

6 (6.38)

0 (0.00)

0.084

 AmB + FCZ+  5-FC

15 (10.00)

13 (13.83)

2 (3.57)

0.050

 AmB + VCZ+ 5-FC

27 (18.00)

24 (25.53)

3 (5.36)

0.002

  1. AmB amphotericin B, FCZ fluconazole, VCZ voriconazole, 5-FC 5-flucytosine